Subscribe
shutterstock_1211592892_hannakuprevich1
hannakuprevich / shutterstock
21 March 2019Big Pharma

Seven new drugs to join $1bn club by 2021, says Clarivate

Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Clarivate announces new Life Science Alliances programme
12 February 2019   Global information company Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.


Editor's picks

Europe
EPO report reveals leading tech investors in Europe
16 January 2025

Editor's picks

Europe
EPO report reveals leading tech investors in Europe
16 January 2025
Americas
EOFlow ordered to pay rival $452m over insulin patch trade secrets
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024

More on this story

Americas
Clarivate announces new Life Science Alliances programme
12 February 2019   Global information company Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.

More on this story

Americas
Clarivate announces new Life Science Alliances programme
12 February 2019   Global information company Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.

More features

Novartis stops rival’s launch of Entresto generic
Maucher Jenkins lands nine-strong team from rival boutique
EPO report reveals leading tech investors in Europe
K&L Gates adds litigator in Melbourne
Gowling WLG’s legal director jumps to Osborne Clarke
Novartis wins appeal in MSN clash over heart drug generic
Takeda loses AMR treatment patent used in kidney transplants
Withers & Rogers hires cell and gene therapy expert